Stevens-johnson syndrome associated with mogamulizumab-induced deficiency of regulatory T cells in an Adult T-cell Leukaemia patient

Acta Dermato-Venereologica

Volumn 95, Issue 5, 2015, Pages 606-607

  Honda, Tetsuya ^a   Hishizawa, Masakatsu ^a   Kataoka, Tatsuki R ^a   Ohmori, Katsuyuki ^b   Takaori Kondo, Akifumi ^a   Miyachi, Yoshiki ^a   Kabashima, Kenji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIFLUPREDNATE; METHYLPREDNISOLONE; MOGAMULIZUMAB; PREDNISOLONE; TACROLIMUS; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CD8+ T LYMPHOCYTE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; PAPULE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEVENS JOHNSON SYNDROME; T CELL LEUKEMIA; CANCER STAGING; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; FOLLOW UP; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MOUTH MUCOSA; NEEDLE BIOPSY; PATHOLOGY; RISK ASSESSMENT; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR INVASION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOPSY, NEEDLE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MALE; MIDDLE AGED; MOUTH MUCOSA; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RISK ASSESSMENT; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84928168827     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2027     Document Type: Article

References (6)

1. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215.
2. Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182: 8071-8079.
3. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-3634.
4. Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013; 104: 647-650.
5. Ishida T, Ueda R. Antibody therapy for adult T-cell leukemia- lymphoma. Int J Hematol 2011; 94: 443-452.
6. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemialymphoma: a multicenter phase II study. J Clin Oncol 2012; 30: 837-842.